MabSpace Biosciences has merged with HJB to create a fully-integrated biotherapeutics company named Transcenta Holding.
Transcenta will have more than ten new molecules in the pipeline and will aim to reduce the time between a target and regulatory submissions.
The company will support the development and marketing of the pipeline molecules through its GMP facility.
It will also collaborate with global biotech companies for the expansion of its portfolio and technological capabilities.
MabSpace and HJB have raised approximately $160m from investors including Lilly Asia Ventures, Temasek, Sequoia China, ARCH Venture Partners, Teng Yue Partners, and Taikang.
Both based in China, MabSpace is a biotechnology company, while HJB is a bioprocessing technologies provider.
Cambrex has completed the acquisition of Avista Pharma Solutions from US-based private equity firm Ampersand Capital Partners.
The acquisition will bolster Cambrex’s position as an integrated small molecule contract development and manufacturing organisation (CDMO).
It will add Avista’s full range of early-stage development capabilities and boost Cambrex’s larger scale capabilities of developing APIs and finished dosage forms.
Both companies involved in the transaction are CDMOs based in the US.
Hetero Lab’s European subsidiary Amarox Limited has acquired Tarbis Farma.
The acquisition will boost Amarox’s product portfolio, commercial infrastructure, manpower, and marketing network.
Hetero Labs is a pharmaceutical company based in India, while Tarbis Farma is a Spanish pharmaceutical company.
Croda International has agreed with Brenntag Nordic to acquire Brenntag Biosector in a €72m ($82.3m) deal.
Brenntag Biosector will become part of Croda’s healthcare business under the life sciences sector.
The acquisition will boost Croda’s portfolio with the addition of a wide range of aluminium and saponin-based adjuvants and strengthen its presence in the vaccines market.
Croda is a British chemicals company, while Brenntag Biosector is a pharmaceutical company based in Denmark.
Fuji Pharma has acquired a 4.2% stake in Alvotech for approximately $50m.
The transaction means the key shareholders in Alvotech will be Aztiq Pharma, Alvogen and Fuji Pharma.
Alvotech and Fuji Pharma previously signed an agreement to co-develop and commercialise biosimilars in Japan. The new investment will strengthen the partnership between the two companies.
Fuji Pharma is a Japanese pharmaceutical company, while Alvotech is a biopharmaceutical company based in Iceland.